Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
Sydney, Australia 7 November 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its United States-based diagnostic trial, SABRE (NCT05407311)1, for participants…